Caribou Biosciences, Inc.
CRBU Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.53
KIRA · Stoqly’s AI analyst, in plain words
- Caribou Biosciences, Inc. had $11.2M of revenue in fiscal 2025, up 11.7% on the year before. Over five years, revenue changed −2.0% a year on average.
- Its operating margin was −1,329.4%, up 337.8 pts: of every 100 in sales, about −1,329 is left after running the business.
- Caribou Biosciences, Inc. lost $148M in fiscal 2025.
- Free cash flow was −$112M in fiscal 2025, −1,006.8% of revenue.
Market cap
$53.8M
P/E
—
Revenue
$11.2M
Net income
−$148M
Free cash flow
−$112M
Operating margin
−1,329.4%
Caribou Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+11.7%
Yes. Sales grew 11.7% last year.
Does it make a profit?
−1,327.4%
No. It lost money last year.
Does profit turn into cash?
−1,006.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Caribou Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Caribou Biosciences, Inc.
- CIK
- 0001619856
Caribou Biosciences, Inc. · CRBU
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $9.6M | $13.9M | $34.5M | $10.0M | $11.2M |
| Revenue growth | −22.4% | 44.3% | 148.9% | −71.0% | 11.7% |
| Operating margin | −697.8% | −768.2% | −336.6% | −1,667.2% | −1,329.4% |
| Net income | −$66.9M | −$99.4M | −$102M | −$149M | −$148M |
| Net margin | −697.3% | −717.8% | −296.1% | −1,491.9% | −1,327.4% |
| Diluted EPS | −$2.11 | −$1.64 | −$1.38 | −$1.65 | −$1.59 |
| Cash | |||||
| Cash from operations | −$32.5M | −$91.0M | −$93.3M | −$138M | −$111M |
| Capital expenditure | $2.1M | $6.5M | $11.6M | $4.9M | $1.4M |
| Free cash flow | −$34.6M | −$97.4M | −$105M | −$143M | −$112M |
| FCF margin | −360.9% | −703.3% | −304.3% | −1,431.7% | −1,006.8% |
| Share count change | 270.5% | 92.0% | 21.4% | 22.4% | 3.4% |
| Debt and strength | |||||
| Cash and short-term investments | $376M | $248M | $329M | $210M | $139M |
| Shareholders' equity | $388M | $301M | $368M | $253M | $122M |
| Current ratio | 15.1x | 9.3x | 12.0x | 7.2x | 5.7x |
| Interest coverage | −8,372.4x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −36.7% | −28.9% | −30.5% | −48.0% | −79.0% |
| Return on tangible equity | −17.3% | −33.0% | −27.7% | −58.9% | −121.2% |
| Piotroski F-score | 3 | 2 | 4 | 1 | 2 |
| Altman Z'' | 11.1 | 4.8 | 6.7 | 0.1 | −9.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
4 insiders
Of sales under plans
62%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Caribou Biosciences, Inc. · CRBU
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.53 a share, the company is worth $53.8M.
Source: SEC EDGAR XBRL filings (CIK 0001619856). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.